Evidence map›Paper›PMID 41018617›Full record

ArticleACS omega2025

Anna Raphaella Autran Colaço, Priscila de Souza Furtado, Daniel Figueiredo Vanzan, Nicole Serqueira da Silva, Flávia Almada do Carmo, Lucio Mendes Cabral, Alice Simon, Jônatas Caldeira Esteves, Plínio Cunha Sathler

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anna Raphaella Autran ColaçoDepartamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Ilha do Fundão, CEP 21941-902 Rio de Janeiro, Rio de Janeiro, Brazil.
Priscila de Souza FurtadoDepartamento de Fármacos e Medicamentos, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Ilha do Fundão, CEP 21941-902 Rio de Janeiro, Rio de Janeiro, Brazil.ORCID https://orcid.org/0000-0002-5265-5493
Daniel Figueiredo VanzanDepartamento de Fármacos e Medicamentos, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Ilha do Fundão, CEP 21941-902 Rio de Janeiro, Rio de Janeiro, Brazil.
Nicole Serqueira da SilvaDepartamento de Clínica Odontológica, Faculdade de Odontologia, Universidade Federal do Rio de Janeiro, Ilha do Fundão, CEP 21941-902 Rio de Janeiro, Rio de Janeiro, Brazil.
Flávia Almada do CarmoDepartamento de Fármacos e Medicamentos, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Ilha do Fundão, CEP 21941-902 Rio de Janeiro, Rio de Janeiro, Brazil.ORCID https://orcid.org/0000-0003-0474-9070
Lucio Mendes CabralDepartamento de Fármacos e Medicamentos, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Ilha do Fundão, CEP 21941-902 Rio de Janeiro, Rio de Janeiro, Brazil.
Alice SimonDepartamento de Fármacos e Medicamentos, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Ilha do Fundão, CEP 21941-902 Rio de Janeiro, Rio de Janeiro, Brazil.
Jônatas Caldeira EstevesDepartamento de Clínica Odontológica, Faculdade de Odontologia, Universidade Federal do Rio de Janeiro, Ilha do Fundão, CEP 21941-902 Rio de Janeiro, Rio de Janeiro, Brazil.
Plínio Cunha SathlerDepartamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Ilha do Fundão, CEP 21941-902 Rio de Janeiro, Rio de Janeiro, Brazil.ORCID https://orcid.org/0000-0003-1203-3179

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Synthetic, biocompatible, and biodegradable polymers such as poly-l-lactic acid (PLLA) and polycaprolactone (PCL) are used in the form of microparticles (25-200 μm) dispersed in injectable hydrogels for collagen biostimulation through mechanical stimuli and subclinical inflammatory responses. However, their clinical application is limited by adverse effects, including nodule formation and vascular occlusion. As an alternative, nanoparticles based on poly-(lactic-

Identifiers

PMID41018617
PMCPMC12461425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.